Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data: https://t.co/u4TTLLjvaq

Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease.

$SAVA #Alzheimers #stocks https://t.co/c4FshQbD5P